Study S001779

A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05669599
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 592
Start: 2023-01-18
Primary completion: 2024-10-08
Lead sponsor: Amgen
Conditions: Obesity; Overweight; Type 2 Diabetes Mellitus
Interventions: BIOLOGICAL:Maridebart Cafraglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: CTIS:2023-510470-13-00; NIH:2023

Registered primary outcomes

Percent Change From Baseline to Week 52 in Body Weight [Baseline and Week 52]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010656	Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. Jastreboff AM, The New England journal of medicine	2025	Randomized trial	PMID 40549887 DOI	cites ClinicalTrials.gov:NCT05669599; registry reference BACKGROUND:40549887